Am Fam Physician. 1999;59(1):35-
During the past decade, several landmark trials have confirmed the benefits of angiotensin converting enzyme (ACE) inhibitor therapy for use in patients with heart failure and patients with recent acute myocardial infarction. Despite the strongly favorable evidence and guideline recommendations, ACE inhibitor therapy remains underused. This editorial reviews the benefits of ACE inhibitor therapy and recent studies describing its lack of utilization in patients and emphasizes the need for broader use of ACE inhibitor therapy.
The clinical impact of heart failure is devastating, and the incidence of this disease has increased steadily in recent years. In the United States, approximately 4.9 million patients (2.5 million men and 2.4 million women) have congestive heart failure.1 About 400,000 new cases of heart failure are reported every year, and it is the single most frequent cause of hospitalization for persons 65 years of age or older. The five-year mortality rate for those with heart failure approaches 50 percent, and more than one half have underlying coronary artery disease.2 This year, an estimated 700,000 persons in our country will survive a myocardial infarction, and 20 percent will be disabled by heart failure within six years. It was estimated that the direct and indirect costs of treating patients with congestive heart failure in the United States in 1998 was $20.2 billion.1
ACE inhibitors are the only medical therapy to date that has been shown in multiple large trials to improve symptoms and prolong life in patients with congestive heart failure. In the past, digoxin, diuretics and vasodilator therapy formed the primary basis for the treatment of heart failure, but now ACE inhibitors are accepted as the mainstay of therapy. A meta-analysis3 of 32 randomized clinical trials studying ACE inhibitor therapy in patients with symptomatic heart failure confirmed their benefit in reducing mortality and recurrent hospitalization for heart failure. Results of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial4 show improved survival for patients with moderate heart failure who are treated with ACE inhibitors; the results suggest that treatment of 1,000 such patients for three years will prevent 50 deaths and 350 hospitalizations.
ACE inhibitor therapy has also been shown to improve survival in patients with acute myocardial infarction. A meta-analysis5 of eight randomized trials enrolling more than 100,000 patients confirmed a reduction in mortality in those who received oral ACE inhibitors within 24 hours after admission. Among selected patients with a left ventricular ejection fraction of less than 40 percent, anterior infarction or clinical signs of congestive heart failure who are treated with ACE inhibitors for one to four years, a survival benefit of 42 to 76 lives per 1,000 treated patients has been observed.
Major guideline statements emphasize the importance of ACE inhibitor therapy for the treatment of patients with heart failure and those with acute myocardial infarction. The Agency for Health Care Policy and Research clinical practice guidelines for the evaluation and care of patients with heart failure secondary to left ventricular systolic dysfunction6 state the following:
The American College of Cardiology/American Heart Association guidelines for the management of patients with acute myocardial infarction7 recommend ACE inhibitor therapy in the following situations:
Despite these strong guideline recommendations, several studies document underuse of therapy with ACE inhibitors in patients who have had a recent myocardial infarction and in those with systolic heart failure.8–10 The Cooperative Cardiovascular Project (CCP) pilot study8 in Medicare patients surviving acute myocardial infarction revealed that more than 40 percent of those who were candidates for ACE inhibitor therapy based on current guidelines did not receive treatment on discharge from the hospital.
Recently, Stafford and colleagues9 evaluated national patterns of use of ACE inhibitor therapy for patients with congestive heart failure by reviewing data from the National Ambulatory Medical Care Surveys from 1989 through 1994. Despite the proven efficacy of ACE inhibitor therapy for congestive heart failure, less than 31 percent of patients who were candidates received therapy. In the largest study of practices among United States physicians to date, Sueta and colleagues10 evaluated data on the use of ACE inhibitor therapy in 16,576 patients with heart failure that were derived from a national database of cardiology and multispecialty practices. Overall, 50 percent of patients received ACE inhibitor therapy, and only 36 percent were prescribed the recommended target dose.
Thus, despite impressive evidence attesting to the efficacy of ACE inhibitor therapy in heart failure and after myocardial infarction, large numbers of patients who might otherwise benefit from these therapies remain untreated. Of particular concern, as noted in the study by Stafford and collegues,9 was the low use of ACE inhibitor therapy among diabetic patients with heart failure, a group in which treatment would not only improve the symptoms and survival from heart failure but also reduce the progression of diabetic nephropathy.11
Broader discussion of guidelines for ACE inhibitor therapy in patients with heart failure and after myocardial infarction should increase the use of these therapies. In addition, both the development of failure teams and the implementation of critical pathways for patients hospitalized with heart failure and myocardial infarction will broaden the implementation of ACE inhibitor therapy.
Deedwania has recently reviewed12 several factors that appear to limit physician use of ACE inhibitors. These factors include the following: (1) concern about hypotension, (2) the presence of coexisting renal insufficiency and (3) cough secondary to ACE inhibitor therapy. Initiating therapy at the lowest available dose and decreasing diuretics for two to three days when starting therapy is generally effective in avoiding hypotension. ACE inhibitors can usually be started safely in patients with serum creatinine levels of less than 2.5 mg per dL (220 μmol per L). They should be discontinued in patients with renal artery stenosis because significant and quick elevations in creatinine levels may occur when ACE inhibitors are prescribed in this setting. Cough has been noted to occur in as many as 20 to 30 percent of patients with heart failure during long-term therapy. Sometimes, switching to a different ACE inhibitor can effectively decrease the incidence of cough; if not, it may be necessary to consider the new angiotensin-II receptor blockers, which have been associated with a lower incidence of cough.13
In summary, the major studies and evidence to date confirm improved outcomes for patients with congestive heart failure and recent myocardial infarction who are treated with ACE inhibitor therapy. Family practitioners and cardiovascular subspecialists must become familiar with existing guidelines and implement ACE inhibitor therapy broadly for appropriate candidates. The impact of widespread use of these therapies would be a profound change in the subsequent course and outcome for millions of patients who have had a myocardial infarction and for those with congestive heart failure.